research centers on regulating cellular pathways associated with aging, particularly mTOR/TORC1 signaling, with the goal of improving skin resilience, function, and long-term health. The company is developing a pipeline of therapeutic and skincare products based on its proprietary technology platform. Its lead technologies include RLX-201, a longevity-focused molecule used in professional skincare products, and RLX-202, a selective TORC1 inhibitor being developed for dermatological disorders. These programs are designed to restore cellular balance, support skin renewal, and address chronic skin conditions linked to dysregulated cellular aging processes.

The company works with dermatologists, researchers, and healthcare professionals to translate advances in longevity science into clinical and commercial applications. Its activities span drug development, dermatology research, professional skincare, and skin longevity technologies, positioning the company at the intersection of biotechnology, dermatology, and healthy aging. In addition to therapeutics and skincare products, Rapalogix Health is developing skin health assessment technologies in collaboration with partners in artificial intelligence and molecular diagnostics. These tools are intended to measure skin function, biological age, and resilience, enabling more personalized approaches to skin health management and longevity-focused care.